Takeda, Sanford-Burnham Ink Obesity Discovery Deal To Explore Non-CNS Options
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical Co. Ltd. and the Sanford-Burnham Medical Research Institute have formed a collaboration focused on identifying and validating new targets and pathways outside of the central nervous system for treating obesity
You may also be interested in...
More Obesity Setbacks For Amylin And Takeda
Neither Amylin Pharmaceuticals Inc. nor its Japanese partner Takeda Pharmaceutical Company Limited has had an easy time of late with diabetes and obesity R&D, and the hold on development for their joint obesity combination therapy shows prospects aren't improving for the firms or the field
More Obesity Setbacks For Amylin And Takeda
Neither Amylin Pharmaceuticals Inc. nor its Japanese partner Takeda Pharmaceutical Company Limited has had an easy time of late with diabetes and obesity R&D, and the hold on development for their joint obesity combination therapy shows prospects aren't improving for the firms or the field
More Obesity Setbacks For Amylin And Takeda
A Phase II trial for their Symlin-based combination therapy was halted after safety issues cropped up with patients from a previous study.